Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

Description

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance. Front Matter ....Pages i-xx Resistance of Colorectal Tumors to Anti-EGFR Antibodies (Livio Trusolino, Simonetta M. Leto)....Pages 1-27 Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK (Maicol Mancini, Yosef Yarden)....Pages 29-49 Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer (Jennifer L. Hsu, Mien-Chie Hung)....Pages 51-66 Mechanisms of Resistance to Molecular Therapies Targeting the HGF/MET Axis (Simona Corso, Silvia Giordano)....Pages 67-87 RAF, MEK and ERK Inhibitors as Anti-Cancer Drugs: Intrinsic and Acquired Resistance as a Major Therapeutic Challenge (Galia Maik-Rachline, Izel Cohen, Rony Seger)....Pages 89-116 Mechanisms of Resistance to PI3K and AKT Inhibitors (Pau Castel, Maurizio Scaltriti)....Pages 117-146 Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy (Konstantinos V. Floros, Anthony C. Faber, Hisashi Harada)....Pages 147-180 Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors (Wolf Ruprecht Wiedemeyer)....Pages 181-210 Resistance to Inhibitors of Angiogenesis (Nili Dahan, Ksenia Magidey, Yuval Shaked)....Pages 211-236 Back Matter ....Pages 237-242